SMA patients welcome Natco’s development of generic drug; call for government intervention to ensure access

Though Natco’s generic could cut costs from Roche’s rate of $7,150 to less than $185, activists call for Centre to invoke the Patents Act and ensure affordable access for all spinal muscular atrophy patients